273 related articles for article (PubMed ID: 30404567)
1. Activation of CXCL5-CXCR2 axis promotes proliferation and accelerates G1 to S phase transition of papillary thyroid carcinoma cells and activates JNK and p38 pathways.
Cui D; Zhao Y; Xu J
Cancer Biol Ther; 2019; 20(5):608-616. PubMed ID: 30404567
[TBL] [Abstract][Full Text] [Related]
2. Activated CXCL5-CXCR2 axis promotes the migration, invasion and EMT of papillary thyroid carcinoma cells via modulation of β-catenin pathway.
Cui D; Zhao Y; Xu J
Biochimie; 2018 May; 148():1-11. PubMed ID: 29471001
[TBL] [Abstract][Full Text] [Related]
3. CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF-κB pathway in colorectal cancer.
Chen C; Xu ZQ; Zong YP; Ou BC; Shen XH; Feng H; Zheng MH; Zhao JK; Lu AG
Cell Death Dis; 2019 Feb; 10(3):178. PubMed ID: 30792394
[TBL] [Abstract][Full Text] [Related]
4. The CXCL5/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis.
Romero-Moreno R; Curtis KJ; Coughlin TR; Miranda-Vergara MC; Dutta S; Natarajan A; Facchine BA; Jackson KM; Nystrom L; Li J; Kaliney W; Niebur GL; Littlepage LE
Nat Commun; 2019 Sep; 10(1):4404. PubMed ID: 31562303
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation.
Jeong WJ; Mo JH; Park MW; Choi IJ; An SY; Jeon EH; Ahn SH
Cancer Biol Ther; 2011 Sep; 12(5):458-65. PubMed ID: 21725210
[TBL] [Abstract][Full Text] [Related]
6. CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling.
Zhou SL; Zhou ZJ; Hu ZQ; Li X; Huang XW; Wang Z; Fan J; Dai Z; Zhou J
Cancer Lett; 2015 Mar; 358(2):124-135. PubMed ID: 25462858
[TBL] [Abstract][Full Text] [Related]
7. Spinal CXCL5 contributes to nerve injury-induced neuropathic pain via modulating GSK-3β phosphorylation and activity in rats.
Xu W; Zhu M; Yuan S; Yu W
Neurosci Lett; 2016 Nov; 634():52-59. PubMed ID: 27717828
[TBL] [Abstract][Full Text] [Related]
8. Tumor-derived CXCL5 promotes human colorectal cancer metastasis through activation of the ERK/Elk-1/Snail and AKT/GSK3β/β-catenin pathways.
Zhao J; Ou B; Han D; Wang P; Zong Y; Zhu C; Liu D; Zheng M; Sun J; Feng H; Lu A
Mol Cancer; 2017 Mar; 16(1):70. PubMed ID: 28356111
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer.
Li A; King J; Moro A; Sugi MD; Dawson DW; Kaplan J; Li G; Lu X; Strieter RM; Burdick M; Go VL; Reber HA; Eibl G; Hines OJ
Am J Pathol; 2011 Mar; 178(3):1340-9. PubMed ID: 21356384
[TBL] [Abstract][Full Text] [Related]
10. CXCL5/CXCR2 modulates inflammation-mediated neural repair after optic nerve injury.
Liu YF; Liang JJ; Ng TK; Hu Z; Xu C; Chen S; Chen SL; Xu Y; Zhuang X; Huang S; Zhang M; Pang CP; Cen LP
Exp Neurol; 2021 Jul; 341():113711. PubMed ID: 33785307
[TBL] [Abstract][Full Text] [Related]
11. The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth.
Li X; Li Z; Song Y; Liu W; Liu Z
Cell Physiol Biochem; 2018; 46(2):579-590. PubMed ID: 29617677
[TBL] [Abstract][Full Text] [Related]
12. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
[TBL] [Abstract][Full Text] [Related]
13. Necroptosis in pancreatic cancer promotes cancer cell migration and invasion by release of CXCL5.
Ando Y; Ohuchida K; Otsubo Y; Kibe S; Takesue S; Abe T; Iwamoto C; Shindo K; Moriyama T; Nakata K; Miyasaka Y; Ohtsuka T; Oda Y; Nakamura M
PLoS One; 2020; 15(1):e0228015. PubMed ID: 31999765
[TBL] [Abstract][Full Text] [Related]
14. Over-expression of miR-206 decreases the Euthyrox-resistance by targeting MAP4K3 in papillary thyroid carcinoma.
Liu F; Yin R; Chen X; Chen W; Qian Y; Zhao Y; Jiang Y; Ma D; Hu T; Yu T; Zhu Y; Zhang Y
Biomed Pharmacother; 2019 Jun; 114():108605. PubMed ID: 30904818
[TBL] [Abstract][Full Text] [Related]
15. Blockage of CXCR2 suppresses tumor growth of intrahepatic cholangiocellular carcinoma.
Sueoka H; Hirano T; Uda Y; Iimuro Y; Yamanaka J; Fujimoto J
Surgery; 2014 Apr; 155(4):640-9. PubMed ID: 24582495
[TBL] [Abstract][Full Text] [Related]
16. Crosstalk between head and neck cancer cells and lymphatic endothelial cells promotes tumor metastasis via CXCL5-CXCR2 signaling.
Lee BS; Jang JY; Seo C; Kim CH
FASEB J; 2021 Jan; 35(1):e21181. PubMed ID: 33231340
[TBL] [Abstract][Full Text] [Related]
17. Increased type 3 deiodinase expression in papillary thyroid carcinoma.
Romitti M; Wajner SM; Zennig N; Goemann IM; Bueno AL; Meyer EL; Maia AL
Thyroid; 2012 Sep; 22(9):897-904. PubMed ID: 22823995
[TBL] [Abstract][Full Text] [Related]
18. Chaperone-mediated Autophagy Governs Progression of Papillary Thyroid Carcinoma via PPARγ-SDF1/CXCR4 Signaling.
Zhou H; Xie X; Chen Y; Lin Y; Cai Z; Ding L; Wu Y; Peng Y; Tang S; Xu H
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32556197
[TBL] [Abstract][Full Text] [Related]
19. Iodine regulates G2/M progression induced by CCL21/CCR7 interaction in primary cultures of papillary thyroid cancer cells with RET/PTC expression.
Zhang YY; Liu ZB; Ye XG; Ren WM
Mol Med Rep; 2016 Oct; 14(4):3941-6. PubMed ID: 27574129
[TBL] [Abstract][Full Text] [Related]
20. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
Devapatla B; Sharma A; Woo S
PLoS One; 2015; 10(9):e0139237. PubMed ID: 26414070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
